Literature DB >> 7898488

Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.

E Rousseau1, J Gagnon, C Lugnier.   

Abstract

According to their respective elution order, specificity for cAMP and cGMP, their sensitivity to calmodulin, and their modulation by cGMP and rolipram, four cyclic nucleotide phosphodiesterases (PDE) were separated from the cytosol: PDE I (calmodulin-sensitive), PDE II (stimulated by cGMP, PDE IV (cGMP specific-PDE and inhibited by rolipram) and PDE V (cGMP specific). PDE IV (Km = 1.4 microM) was competitively inhibited by rolipram (Ki = 1.2 microM) whereas PDE V (Km = 0.83 microM) was competitively inhibited by zaprinast in the mumolar range (Ki = 0.12 microM). Moreover the microsomal fraction contained three PDE isoforms: PDE II, PDE III (inhibited by cGMP or indolidan) and PDE IV. These results show that cAMP degradation in cytosolic and membrane fractions is modulated by cGMP and selectively inhibited by rolipram and, in addition, by indolidan in membrane fractions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7898488     DOI: 10.1007/bf00926755

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  14 in total

Review 1.  Cystic fibrosis transmembrane conductance regulator: a chloride channel with novel regulation.

Authors:  M J Welsh; M P Anderson; D P Rich; H A Berger; G M Denning; L S Ostedgaard; D N Sheppard; S H Cheng; R J Gregory; A E Smith
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

2.  Large conducting potassium channel reconstituted from airway smooth muscle.

Authors:  D Savaria; C Lanoue; A Cadieux; E Rousseau
Journal:  Am J Physiol       Date:  1992-03

Review 3.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

Review 4.  Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.

Authors:  W J Thompson
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

5.  Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.

Authors:  C Lugnier; B Muller; A Le Bec; C Beaudry; E Rousseau
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

6.  Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene.

Authors:  J A Tabcharani; X B Chang; J R Riordan; J W Hanrahan
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

7.  Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles.

Authors:  R F Kauffman; B G Utterback; D W Robertson
Journal:  Circ Res       Date:  1989-05       Impact factor: 17.367

8.  Adenosine 3:5' cyclic monophosphate synthesis by human tracheal epithelial cells.

Authors:  C M Kercsmar; M D Infeld; C L Silski; P B Davis
Journal:  Am J Respir Cell Mol Biol       Date:  1990-01       Impact factor: 6.914

9.  Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.

Authors:  T J Torphy; H L Zhou; M Burman; L B Huang
Journal:  Mol Pharmacol       Date:  1991-03       Impact factor: 4.436

10.  Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle.

Authors:  M D Ivorra; A Le Bec; C Lugnier
Journal:  J Cardiovasc Pharmacol       Date:  1992-04       Impact factor: 3.105

View more
  4 in total

1.  Phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages.

Authors:  Otgonchimeg Rentsendorj; Franco R D'Alessio; David B Pearse
Journal:  J Leukoc Biol       Date:  2014-07-25       Impact factor: 4.962

2.  Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.

Authors:  Otgonchimeg Rentsendorj; Mahendra Damarla; Neil R Aggarwal; Ji-Young Choi; Laura Johnston; Franco R D'Alessio; Michael T Crow; David B Pearse
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

3.  Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.

Authors:  T J Kelley; L Al-Nakkash; C U Cotton; M L Drumm
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 4.  PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.

Authors:  Claire Lugnier; Hayder M Al-Kuraishy; Eric Rousseau
Journal:  Biochem Pharmacol       Date:  2021-01-28       Impact factor: 6.100

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.